Research location
Southaven
Mississippi, United States
Advertisement
Research activity in Southaven
Mississippi, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 45 trials and 46 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Southaven
45 linked trials · page 1 of 1Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot UlcersNCT07161830 · 2025-12-04 · 1 site observation
RECRUITING
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)NCT07144280 · 2025-09-29 · 1 site observation
RECRUITING
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerNCT06712355 · 2025-02-03 · 1 site observation
RECRUITING
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology ClinicsNCT06418204 · 2025-01-30 · 1 site observation
RECRUITING
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic RetinopathyNCT06321302 · 2024-05-15 · 1 site observation
ACTIVE_NOT_RECRUITING
Nesvategrast (OTT166) in Diabetic Retinopathy (DR)NCT05409235 · 2022-07-29 · 1 site observation
COMPLETED
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382286 · 2022-07-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382299 · 2022-07-20 · 1 site observation
ACTIVE_NOT_RECRUITING
Screening for High Frequency Malignant DiseaseNCT05117840 · 2022-01-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of a High-Dose Aflibercept in Participants With Diabetic Eye DiseaseNCT04429503 · 2020-06-29 · 1 site observation
COMPLETED
A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic RetinopathyNCT04265261 · 2020-06-05 · 1 site observation
COMPLETED
Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate CancerNCT03686683 · 2018-10-18 · 1 site observation
COMPLETED
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast CancerNCT03414970 · 2018-03-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Tele-Exercise and Multiple SclerosisNCT03117881 · 2018-01-08 · 1 site observation
COMPLETED
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesNCT02785913 · 2014-11-01 · 1 site observation
COMPLETED
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02965378 · 2014-10-01 · 1 site observation
COMPLETED
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02785939 · 2014-09-01 · 1 site observation
COMPLETED
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersNCT02766335 · 2014-07-31 · 1 site observation
COMPLETED
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesNCT02926638 · 2014-06-16 · 1 site observation
TERMINATED
Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast CancerNCT02007512 · 2013-12-16 · 1 site observation
COMPLETED
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)NCT01945775 · 2013-10-14 · 1 site observation
COMPLETED
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate CancerNCT01946204 · 2013-10-14 · 1 site observation
ACTIVE_NOT_RECRUITING
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerNCT01674140 · 2013-09-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast CancerNCT01889238 · 2013-06-12 · 1 site observation
COMPLETED
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone TherapyNCT01598298 · 2013-05-15 · 1 site observation
COMPLETED
Cardiovascular Inflammation Reduction TrialNCT01594333 · 2013-04-01 · 1 site observation
COMPLETED
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)NCT01740427 · 2013-02-22 · 1 site observation
COMPLETED
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast CancerNCT01597193 · 2012-04-30 · 1 site observation
COMPLETED
Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRONCT01465802 · 2011-12-26 · 1 site observation
COMPLETED
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate CancerNCT01306890 · 2011-01-27 · 1 site observation
COMPLETED
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast CancerNCT00703326 · 2008-08-06 · 1 site observation
COMPLETED
Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line ChemotherapyNCT00676507 · 2008-07-01 · 1 site observation
COMPLETED
Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel ChemotherapyNCT00676650 · 2008-07-01 · 1 site observation
TERMINATED
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus BevacizumabNCT00625898 · 2008-04-01 · 1 site observation
TERMINATED
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma HistologyNCT00596830 · 2008-04-01 · 1 site observation
TERMINATED
A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.NCT00600821 · 2008-04-01 · 1 site observation
COMPLETED
Dose Range Study of Anamorelin in Patients With Non-small Cell Lung CancerNCT00622193 · 2008-03-01 · 1 site observation
COMPLETED
Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.NCT00467844 · 2007-05-01 · 2 site observations
COMPLETED
Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast CancerNCT00322517 · 2006-04-01 · 1 site observation
COMPLETED
Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast CancerNCT00243503 · 2006-02-01 · 1 site observation
COMPLETED
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung CancerNCT00147537 · 2005-02-01 · 1 site observation
COMPLETED
A Study of E7389 in Advanced/Metastatic Breast Cancer PatientsNCT00097721 · 2004-09-01 · 1 site observation
COMPLETED
Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and CapecitabineNCT00072852 · 2003-11-01 · 1 site observation
COMPLETED
Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung CarcinomaNCT00050674 · 2001-11-01 · 1 site observation
COMPLETED
Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed AppropriateNCT02142868 · 1 site observation
NO_LONGER_AVAILABLE
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.